• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.79% Nasdaq Up0.53%

    Ariad Pharmaceuticals Inc. (ARIA)

    -NasdaqGS
    8.09 Down 0.18(2.18%) 4:00PM EDT
    |After Hours : 8.01 Down 0.08 (0.99%) 7:59PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Ariad Pharmaceuticals Inc.
    26 Landsdowne Street
    Cambridge, MA 02139
    United States - Map
    Phone: 617-494-0400
    Fax: 617-494-8144
    Website: http://www.ariad.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:379

    Business Summary 

    ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories. It also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, an orally active TKI for treating non-small cell lung cancer and various other solid tumors. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Ariad Pharmaceuticals Inc.

    Corporate Governance 
    Ariad Pharmaceuticals Inc.’s ISS Governance QuickScore as of Jun 1, 2015 is 8. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 4; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Harvey J. Berger M.D., 65
    Principal Founder, Chairman, Chief Exec. Officer, Pres and Chairman of Exec. Committee
    1.43M78.00K
    Mr. Edward M. Fitzgerald , 60
    Chief Financial Officer, Exec. VP and Treasurer
    706.00K49.00K
    Dr. Timothy P. Clackson Ph.D., 50
    Pres of R&D and Chief Scientific Officer
    890.00K0.00
    Dr. Daniel M. Bollag Ph.D., 54
    Sr. VP of Regulatory Affairs and Quality
    679.00K129.00K
    Mr. Martin J. Duvall , 53
    Chief Commercial Officer and Exec. VP
    717.00K0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders